Patent ID: 8273780

Claim:
A method of treating lung fibrosis, renal fibrosis, liver fibrosis, or melanoma, in a mammal comprising administering to said mammal a therapeutically effective amount of a compound according to the following Formula (I), or a pharmaceutically acceptable salt thereof: wherein, R 1 is —CO 2 H, —CO 2 R D , —CN, —C(═O)N(R 9 ) 2 , —C(═O)NHCH 2 CH 2 SO 3 H, —C(═O)NHSO 2 R 10 , tetrazolyl, or 5-oxo-2,5-dihydro-[1,2,4]oxadiazol-3-yl; R D is H or C 1 -C 4 alkyl; R 3 is H, C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, or C 1 -C 4 fluoroalkyl; R 4 is —NR 7 C(═O)OCH(R 8 )—CY; R 7 is H or C 1 -C 4 alkyl; R 8 is H, C 1 -C 4 alkyl, or C 1 -C 4 fluoroalkyl; CY is a substituted or unsubstituted C 3 -C 6 cycloalkyl or a substituted or unsubstituted phenyl, wherein if CY is substituted then CY is substituted with 1 or 2 R C ; R 9 is H, C 1 -C 6 alkyl, C 1 -C 6 -fluoroalkyl, C 3 -C 6 cycloalkyl, or a substituted or unsubstituted phenyl; R 10 is a C 1 -C 6 alkyl, C 1 -C 6 -fluoroalkyl, C 3 -C 6 cycloalkyl, or a substituted or unsubstituted phenyl; each of R A , R B , and R C are independently selected from F, Cl, Br, I, —CN, —OH, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 fluoroalkoxy, C 1 -C 4 alkoxy, and C 1 -C 4 heteroalkyl; m is 0, 1, or 2; n is 1, 2, 3 or 4; and p is 0, 1, or 2; in combination with at least one additional agent selected from the group consisting of an immunosuppressant, an anti-inflammatory agent, and an agent used in the treatment of a respiratory condition.